Study in Subjects With Light Chain (AL) Amyloidosis
ID de estudio #: NCT03154047
condición: Amiloidosis AL
The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
última actualización: 17 de Septiembre de 2021
fecha de inicio: 14 de junio de 2017
finalización estimada: 30 de mayo de 2018
última actualización: Marzo 26, 2019
fase de desarrollo: la Fase 2 de ATLAS
tamaño / inscripción: 80
descripción del estudio: Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and completed Study NEOD001-201. Subjects in this study may receive concomitant chemotherapy. Subject screening will occur during the 28 days prior to the first administration of study drug, which may overlap with the last visit in Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and Screening assessments will be completed. Study visits will occur every 28 days based on scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1. Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug. Each subject's study participation may be up to 38 months or until the study is terminated, whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase (36 months), and EOS Visit (30 [±5] days after the last dose).
- Number of Participants With Adverse Events
AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
- Each subject's study participation may have been up to 36 months or until the study was terminated
criterios de inclusión:
• Sexos elegibles: todos
Completed the End of Study Visit in Study NEOD001-201
Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:
Absolute neutrophil count (ANC) ≥1.0 × 109/L
Recuento de plaquetas ≥75 × 109/L
Hemoglobina ≥9 g/dL
Total bilirubin ≤2 × upper limit of normal (ULN)
Aspartate aminotransferase (AST) ≤3 × ULN
Alanine aminotransferase (ALT) ≤3 × ULN
Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, or measured GFR ≥25 mL/min/1.73 m2
Systolic blood pressure 80-180 mmHg
Women of childbearing potential must have a negative pregnancy test during Screening and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
Capacidad para comprender y voluntad para firmar un formulario de consentimiento informado antes del inicio de cualquier procedimiento de estudio
Criterio de exclusión: Criterios:
Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiographic (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continuation or initiation of treatment with NEOD001 or participation in the study
Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments
Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
First degree atrioventricular (AV) block
Second degree AV block Type 1 (Mobitz Type 1/ Wenckebach type)
Bloqueo de rama derecha o izquierda
Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., >110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])
Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events [CTCAE] ≥Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects who have received treatment with a proteasome inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy.
Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:
Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note: In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study.
Factores de crecimiento hematopoyético, transfusiones de sangre o productos sanguíneos dentro de 1 semana
Chemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed therapy within 2 weeks
ASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4 weeks before Month 1-Day 1 of this study)
Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor)
Planned organ transplant during the study
Any investigational agent, other than NEOD001, within 4 weeks
Any experimental imaging agent directed at amyloid within 2 weeks
Active malignancy with the exception of any of the following:
Carcinoma de células basales, carcinoma de células escamosas o cáncer de cuello uterino in situ adecuadamente tratado
Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
Low-risk prostate cancer with Gleason score <7 and prostate-specific antigen <10 mg/mL
Cualquier otro cáncer del que el sujeto haya estado libre de enfermedad durante ≥2 años
History of Grade ≥3 infusion-related adverse events (AEs) or hypersensitivity to NEOD001
History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20
Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection
Mujeres que están amamantando
Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study
Unable or unwilling to adhere to the study-specified procedures and restrictions
Subject is under legal custodianship
Amiloidosis hereditaria de la cadena A de fibrinógenoLa amiloidosis es una enfermedad rara causada por ...
¿Puedo hacer ejercicio si tengo amiloidosis AL?Se cree que el ejercicio es beneficioso ...
Síntomas de neuropatía periférica, pruebas de diagnóstico y tratamientos aprobados - Seminario web de ASG 7/11https://www.youtube.com/watch?v=K2TmwAfu...
Amiloidosis y su manejo: neuropatías amiloidesLas neuropatías amiloides son raras, rápidas ...
Fundación de Defensa del PacientePatient Advocate Foundation es una natio ...
Insuficiencia cardíaca resultante de la enfermedad amiloide cardíaca relacionada con la edad asociada con la transtiretina de tipo salvaje: una perspectiva ...Antecedentes: insuficiencia cardíaca causada por ...
Raymond L. Comenzo, MDEl Dr. Raymond Comenzo recibió a su médico ...
La configuración de cookies en este sitio web se establece en "permitir cookies" para darle la mejor experiencia de navegación posible. Si usted continúa utilizando este sitio web sin cambiar la configuración de cookies o hacer clic en "Aceptar" El consentimiento de abajo y usted tiene que esto.